FDA Approves Tralokinumab-ldrm Autoinjector for Adults With …
Jun 13, 2024 · The FDA has approved a new tralokinumab-ldrm (Adbry; LEO Pharma) 300 mg single-dose autoinjector for adult patients with moderate-to-severe atopic dermatitis. …
FDA Approves Adbry for Treatment of Moderate-to-Severe Atopic ...
Jan 3, 2022 · The FDA has approved tralokinumab-ldrm (Adbry, LEO Pharma) for the treatment of moderate-to-severe atopic dermatitis (AD) for adults whose disease is not well controlled with …
Navigating Pediatric Atopic Dermatitis: Insights Into Treatment ...
Jan 31, 2025 · Tralokinumab-ldrm (Adbry; LEO Pharma Inc) and, more recently, lebrikizumab-lbkz (Ebglyss; Eli Lilly and Company) are IL-13 inhibitors approved for moderate to severe disease …
Daily Medication Pearl: Tralokinumab-ldrm (Adbry) - Pharmacy …
Jan 11, 2022 · Medication Pearl of the Day: Tralokinumab-ldrm (Adbry) Indication: Tralokinumab-ldrm (Adbry) is an interleukin-13 (IL-13) antagonist indicated for the treatment of moderate-to …
A Pharmacist’s Guide to Blockbuster Patent ... - Pharmacy Times
Apr 18, 2025 · This year is shaping up to be a turning point in the pharmaceutical landscape, with several blockbuster drugs losing their patent protection and opening the floodgates for …
Experts: Current Treatment Regimens and the Future for Plaque …
Feb 26, 2024 · In addition to current treatment regimens, 2 experts discuss how available options can vary between adult and pediatric patients.
Ozempic, Biktarvy Among the Drugs Seeing List Price Increases at …
Key Takeaways January 1, 2025, marked significant brand drug price changes, with 590 adjustments, predominantly increases, and only 7 decreases. Notable drugs like Biktarvy, …
FDA Approves Dupilumab for Treatment of Bullous Pemphigoid
Jun 20, 2025 · The FDA approves dupilumab as the first targeted treatment for bullous pemphigoid, offering hope for patients with this debilitating skin condition.
Tralokinumab-ldrm Shows Significant Improvements in
Feb 10, 2022 · Treatment with tralokinumab-ldrm (Adbry; LEO Pharma) produced significant improvements in itch, sleep interference, anxiety, depression, and overall quality of life among …
FDA Approves Lebrikizumab for Treatment of Atopic Dermatitis
Sep 16, 2024 · Lebrikizumab (Ebglyss; Eli and Lilly Company) received FDA approval for the treatment of adults and children 12 years of age and older who weigh at least 88 pounds (40 …